The biologics fill / finish services market is projected to grow at a CAGR of 8%, till 2035, claims Roots Analysis

A number of biopharmaceutical companies are outsourcing their biologics fill / finish operations, thereby, prompting stakeholders engaged in this domain to undertake several expansion initiatives, to cater to the needs of clients around the globe.

The biologics fill / finish services market is projected to grow at a CAGR of 8%, till 2035, claims Roots Analysis

Roots Analysis has announced the addition of “Biologics Fill Finish Services Market (3rd Edition), 2022-2035” report to its list of offerings. 

Given the growing pipeline of biologics, lack of technical expertise, and huge capital investment in the installation of fill / finish equipment, a number of drug manufacturers are turning to contract service providers in order to ensure the development of quality drug products. This evident surge in the demand for biologics fill / finish services has presented lucrative opportunities for service providers having necessary fill / finish capabilities. 

Key Market Insights

More than 175 service providers claim to offer services for biologic fill / finish operations

The biologics fill / finish market is highly fragmented, featuring a mix of small, mid-sized, and large players. It is worth noting that this market is currently dominated by mid-sized companies (having 51-500 employees), which represent more than 40% of the industry stakeholders, worldwide.


Several partnerships have been established in the biologics fill / finish services domain, since 2013

Nearly 40% of the deals were inked in 2020. Majority of the instances captured in the report were service agreements (60%). In addition, more than 50 deals have been inked by players to offer biologics fill / finish services for vaccines.


Over 170 expansions have been reported in biologics fill / finish services domain, since 2013

More than 50% of the total expansions were focused on enhancing the dedicated capacities, thereby enabling the industry stakeholders to accommodate their growing business and address the surge in the demand for fill / finish services. Further, more than 45% of the expansions involved the establishment of new plant / facilities or adding area to the existing facilities, across different geographical locations.     


The currently available biologics fill / finish capacity is estimated to be over 185 Kiloliters

 Around 90% of the installed fill / finish capacity belongs to the companies with commercial scale production capabilities. In fact, close to 85% of the available capacity belongs to the large companies (having more than 500 employees).


The demand for biologics fill / finish services is expected to grow at an annualized rate of 14%

Currently, more than 60% of the overall demand for biologics fill/ finish services is generated from filling of vials. Moreover, close to 40% of the demand is likely to be generated in the Europe region.


Europe and Asia-Pacific are expected to capture more than 70% of the market share by 2035

In terms of type of biologics, antibodies and vaccines are expected to occupy a larger share (~70%) of the total biologics fill / finish services market in 2035. Further, over 25% of the biologics fill / finish services market share for therapeutic areas is captured by oncological disorders.


To request a sample copy / brochure of this report, please visit this


Key Questions Answered

  • What is fill / finish?
  • Who are the key players offering biologics fill / finish services?
  • Where are biologics fill / finish facilities located?
  • What is the market share of ampoules, cartridges, vials, and syringes in fill / finish?
  • What types of expansion initiatives are being undertaken by players in this domain?
  • What is the current demand for biologics fill / finish services?
  • What is the current and future market size for biologics fill / finish services?


The financial opportunity within the biologics fill / finish services market has been analyzed across the following segments:


  • Type of Packaging Container
  • Ampoules
  • Cartridges
  • Syringes
  • Vials


  • Type of Biologic
  • Antibodies
  • Cell Therapies
  • Gene Therapies
  • Oligonucleotides
  • Proteins / Peptides
  • Vaccines
  • Others


  • Therapeutic Area
  • Oncological Disorders
  • Autoimmune Disorders
  • Infectious Diseases
  • Cardiovascular Disorders
  • Other Disorders


  • Scale of Operation
  • Preclinical / Clinical
  • Commercial


  • Company Size
  • Large
  • Mid-sized
  • Small


  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa
  • Latin America


The report features inputs from eminent industry stakeholders, according to whom, a significant increase in the demand for cell and gene therapies is driving the growth of the biologics fill / finish market. The report includes detailed transcripts of discussions held with the following experts:


  • Gregor Kawaletz (Chief Commercial Officer, IDT Biologika)
  • Matt Delaney (Vice President Business Development & Marketing, Cytovance Biologics)
  • Purushottam Singnurkar (Research Director and Head of Formulation Development, Syngene International)
  • Ales Sima (Business Development Manager, Oncomed Manufacturing)
  • Amit Chandra (Technology Watch Manager, Yposkesi)
  • Jos Vergeest (International Business Developer, HALIX)


The research also includes detailed profiles of key players (listed below) engaged in offering biologics fill / finish services; each profile features a brief overview of the company, its financial information (if available), details on biologics fill / finish services, location of facilities recent developments and an informed future outlook.


  • AbbVie Contract Manufacturing
  • Asymchem
  • BioReliance
  • Boehringer Ingelheim BioXcellence
  • Catalent Biologics
  • Charles River Laboratories
  • Fareva
  • Fresenius Kabi
  • Glaxo SmithKline
  • Hetero Drugs
  • Intas Pharmaceuticals
  • Lonza
  • Patheon
  • Pierre Fabre
  • Recipharm
  • Samsun Biologics
  • Syngene
  • Takara Bio
  • Wacker Biotech
  • WuXi AppTec
  • WuXi Biologics


For additional details, please visit or email


You may also be interested in the following titles:

  1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
  2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.



Ben Johnson

+1 (415) 800 3415